Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Advanced Adrenocortical Carcinoma (Phase II, Open-label)
2018-001802-27Phase 2Completed
- Sponsor
- University Hospital Würzburg
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in adrenal cancer (ACC), sponsored by University Hospital Würzburg. Primary endpoint: progression-free survival at 4 months. Started Dec 2018; status: completed.
02
Drugs
cabozantinib
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on 2018-001802-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001802-27.